MX2022005718A - Anticuerpos tmem219 y usos terapeuticos de los mismos. - Google Patents
Anticuerpos tmem219 y usos terapeuticos de los mismos.Info
- Publication number
- MX2022005718A MX2022005718A MX2022005718A MX2022005718A MX2022005718A MX 2022005718 A MX2022005718 A MX 2022005718A MX 2022005718 A MX2022005718 A MX 2022005718A MX 2022005718 A MX2022005718 A MX 2022005718A MX 2022005718 A MX2022005718 A MX 2022005718A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- tmem219
- therapeutic uses
- namely
- production
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 abstract 1
- 101000680180 Homo sapiens Insulin-like growth factor-binding protein 3 receptor Proteins 0.000 abstract 1
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 abstract 1
- 102100022214 Insulin-like growth factor-binding protein 3 receptor Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a anticuerpos o fragmentos de unión a antígenos de los mismos que se unen específicamente al receptor IGFBP3, concretamente al TMEM219, a métodos para su producción, a composiciones farmacéuticas que contienen dichos anticuerpos y a usos de los mismos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19209521 | 2019-11-15 | ||
EP20167459 | 2020-04-01 | ||
PCT/EP2020/082292 WO2021094620A1 (en) | 2019-11-15 | 2020-11-16 | Tmem219 antibodies and therapeutic uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022005718A true MX2022005718A (es) | 2022-07-12 |
Family
ID=73401537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022005718A MX2022005718A (es) | 2019-11-15 | 2020-11-16 | Anticuerpos tmem219 y usos terapeuticos de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230242649A1 (es) |
EP (1) | EP4058476A1 (es) |
JP (1) | JP2023501229A (es) |
KR (1) | KR20220100611A (es) |
CN (2) | CN114651006A (es) |
AU (1) | AU2020382101A1 (es) |
BR (1) | BR112022008629A2 (es) |
CA (1) | CA3154526A1 (es) |
CL (1) | CL2022001138A1 (es) |
IL (1) | IL292599A (es) |
MX (1) | MX2022005718A (es) |
WO (1) | WO2021094620A1 (es) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5215534A (en) | 1991-12-02 | 1993-06-01 | Lawrence De Harde | Safety syringe system |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
AU2002218166A1 (en) | 2000-09-08 | 2002-03-22 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
MXPA04001072A (es) | 2001-08-03 | 2005-02-17 | Glycart Biotechnology Ag | Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada. |
BR0213761A (pt) | 2001-10-25 | 2005-04-12 | Genentech Inc | Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2544865C (en) | 2003-11-05 | 2019-07-09 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
AU2005286607B2 (en) | 2004-09-23 | 2011-01-27 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
US20090170133A1 (en) * | 2005-04-19 | 2009-07-02 | Irena Kirman | Intact IGFBP-3 as a Colon Cancer Risk Factor in Patients With Inflammatory Bowel Disease |
US9427531B2 (en) | 2010-06-28 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Auto-injector |
US9248242B2 (en) | 2012-04-20 | 2016-02-02 | Safety Syringes, Inc. | Anti-needle stick safety device for injection device |
US20140155827A1 (en) | 2012-12-03 | 2014-06-05 | Mylan, Inc. | Medicament information system and method |
NZ738100A (en) | 2015-06-04 | 2019-09-27 | Ospedale San Raffaele Srl | Igfbp3 and uses thereof |
AU2016272045B2 (en) | 2015-06-04 | 2018-04-19 | Ospedale San Raffaele Srl | Inhibitor of IGFBP3/TMEM219 axis and diabetes |
-
2020
- 2020-11-16 CN CN202080077088.0A patent/CN114651006A/zh not_active Withdrawn
- 2020-11-16 US US17/777,021 patent/US20230242649A1/en active Pending
- 2020-11-16 BR BR112022008629A patent/BR112022008629A2/pt unknown
- 2020-11-16 KR KR1020227018605A patent/KR20220100611A/ko unknown
- 2020-11-16 CA CA3154526A patent/CA3154526A1/en active Pending
- 2020-11-16 EP EP20807014.4A patent/EP4058476A1/en active Pending
- 2020-11-16 MX MX2022005718A patent/MX2022005718A/es unknown
- 2020-11-16 WO PCT/EP2020/082292 patent/WO2021094620A1/en active Application Filing
- 2020-11-16 AU AU2020382101A patent/AU2020382101A1/en active Pending
- 2020-11-16 JP JP2022525402A patent/JP2023501229A/ja active Pending
- 2020-11-16 CN CN202310610598.5A patent/CN116478292A/zh active Pending
-
2022
- 2022-04-28 IL IL292599A patent/IL292599A/en unknown
- 2022-05-02 CL CL2022001138A patent/CL2022001138A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230242649A1 (en) | 2023-08-03 |
KR20220100611A (ko) | 2022-07-15 |
CA3154526A1 (en) | 2021-05-20 |
CN114651006A (zh) | 2022-06-21 |
WO2021094620A1 (en) | 2021-05-20 |
CL2022001138A1 (es) | 2023-05-12 |
AU2020382101A1 (en) | 2022-06-09 |
CN116478292A (zh) | 2023-07-25 |
JP2023501229A (ja) | 2023-01-18 |
IL292599A (en) | 2022-07-01 |
BR112022008629A2 (pt) | 2022-07-19 |
EP4058476A1 (en) | 2022-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
MX2021002970A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor. | |
PH12017500890A1 (en) | Antibody drug conjugates | |
MX2021002969A (es) | Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1. | |
MX2016012830A (es) | Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos. | |
MX369148B (es) | Agentes de unión kir3dl2. | |
MX2022011732A (es) | Conjugados de farmacos y anticuerpos anti-ccr7. | |
MX2019013998A (es) | Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2). | |
TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
MY200162A (en) | Anti-gitr antibodies and uses thereof | |
TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
MX2021002690A (es) | Anticuerpos anti-avb8 y composiciones y usos de los mismos. | |
MX2020002036A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor. | |
PH12019500802A1 (en) | Antibodies that bind zika virus envelope protein and uses thereof | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
PH12019500342A1 (en) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 | |
WO2019100052A3 (en) | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof | |
MX2009008754A (es) | Anticuerpos novedosos contra igf-1r. | |
MX2022005718A (es) | Anticuerpos tmem219 y usos terapeuticos de los mismos. | |
MX2022003523A (es) | Proteinas de union a antigenos. | |
MX2022001882A (es) | Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40. |